| Title |
Author |
Type |
Date |
Words |
| Prionics and Bio-X Diagnostics Form Strategic Partnership. |
|
|
May 13, 2013 |
513 |
| RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States. |
|
|
May 2, 2013 |
886 |
| RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States. |
|
|
May 2, 2013 |
881 |
| Monoclonal Antibody with Xencor's High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia. |
|
|
Apr 26, 2013 |
629 |
| NewLink Genetics Presents Preclinical Data on New IDO Pathway Inhibitor, NLG919, at AACR 2013 Annual Meeting. |
|
|
Apr 8, 2013 |
1154 |
| NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer. |
|
|
Apr 4, 2013 |
938 |
| NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer. |
|
|
Apr 2, 2013 |
1315 |
| Oncolytics Biotech[R] Inc. Meets Primary Overall Statistical Endpoint in U.S. Phase 2 Study of REOLYSIN[R] in Squamous Cell Lung Cancer. |
|
|
Mar 28, 2013 |
908 |
| Research Published in the New England Journal of Medicine Demonstrates Marked and Long-Lasting Antiviral Activity Against HCV for Santaris Pharma A/S' Miravirsen, the First MicroRNA-Targeted Drug to Enter Clinical Trials. |
|
|
Mar 27, 2013 |
1668 |
| The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology's CYT003 for the Treatment of Allergic Asthma. |
|
Clinical report |
Mar 13, 2013 |
975 |
| DCVax-Direct Phase I/II Trial For All Inoperable Solid Tumors Is Expected To Produce Ongoing Results In 2013. |
|
|
Mar 5, 2013 |
1086 |
| Araxes Pharma Enters Into Cancer Drug Discovery and Development Agreement With Janssen Biotech. |
|
|
Feb 27, 2013 |
542 |
| Valent BioSciences to Sell Pace International Preharvest Products through Valent U.S.A. Corporation. |
|
|
Feb 27, 2013 |
768 |
| Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology Industries. |
|
|
Feb 21, 2013 |
1005 |
| Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group. |
|
|
Feb 19, 2013 |
862 |
| ACT's Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company's hESC-derived Cells to Treat Severe Myopia. |
|
|
Feb 11, 2013 |
1064 |
| Oncolytics Biotech[R] Inc. Announces Additional Positive REOLSYIN[R] Clinical Trial Data from Phase 2 Study in Squamous Cell Carcinoma of the Lung. |
|
Report |
Feb 8, 2013 |
836 |
| Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A. |
|
|
Feb 6, 2013 |
989 |
| Daiichi Sankyo and Arqule Enroll First Hepatocellular Carcinoma (HCC) Patient into Global Phase 3 Trial for Tivantinib. |
|
|
Jan 31, 2013 |
1465 |
| Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib. |
|
|
Jan 31, 2013 |
1468 |
| RXi Pharmaceuticals Announces Completion of Enrollment in Second Phase 1 Trial for RXI-109 Program. |
|
|
Jan 30, 2013 |
748 |
| Novus International And Verenium Announce Important Progress In The Development Of Novel Enzymes For Animal Health & Nutrition. |
|
|
Jan 30, 2013 |
1483 |
| Alnylam and Collaborators Publish Results from Phase I Clinical Trial and Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer. |
|
|
Jan 30, 2013 |
2244 |
| Seattle Genetics Announces Data from ASG-5ME Phase I Clinical Trial for Pancreatic Cancer. |
|
|
Jan 25, 2013 |
1237 |
| Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL). |
|
|
Jan 24, 2013 |
2062 |
| Surviving BioTech: How the Game is Played - Phase Funding, Drug Approvals and Resulting Revenue. |
|
|
Jan 14, 2013 |
739 |
| Surviving BioTech: How the Game is Played - Phase Funding, Drug Approvals and Resulting Revenue. |
|
|
Jan 14, 2013 |
745 |
| Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial with Tivantinib in Colorectal Cancer. |
|
|
Jan 11, 2013 |
1802 |
| Eisai Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer. |
|
|
Jan 11, 2013 |
767 |
| Spectrum Pharmaceuticals Announces Positive RenaZorb[R] Phase 1 Clinical Data Demonstrating Robust Activity in Easy-to-Swallow Pill Formulation. |
|
|
Jan 7, 2013 |
1182 |
| Alnylam Files Clinical Trial Application to Initiate a Phase I Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). |
|
|
Jan 3, 2013 |
2205 |
| Fibrocell Science, Inc. to Initiate Phase II Clinical Trial for Restrictive Burn Scars. |
|
Medical condition overview |
Dec 17, 2012 |
1044 |
| ACT Announces Completion of Higher-Dosage Cohort in European Clinical Trial for Stargardt's Macular Dystrophy. |
|
|
Dec 17, 2012 |
785 |
| ArQule Enrolls First Patient in Phase 1 Trial with ARQ 087, an FGFR Inhibitor. |
|
|
Dec 13, 2012 |
825 |
| XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris. |
|
|
Dec 12, 2012 |
731 |
| Data Reported From Phase 1 Study of Once a Week MLN9708 Oral Proteasome Inhibitor in Patients with Relapsed or Refractory Systemic Light-Chain Amyloidosis. |
|
Report |
Dec 10, 2012 |
909 |
| Seattle Genetics Announces Data from Investigator-Sponsored Trials of ADCETRIS[R] (Brentuximab Vedotin) in Cutaneous T-Cell Lymphoma at ASH Annual Meeting. |
|
|
Dec 10, 2012 |
1955 |
| Seattle Genetics Reports Data from Phase I Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting. |
|
|
Dec 10, 2012 |
2212 |
| Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology. |
|
Clinical report |
Dec 10, 2012 |
2939 |
| Seattle Genetics Reports Data from Phase I Trial of ADCETRIS[R] (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL). |
|
|
Dec 9, 2012 |
2103 |
| NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer[R] NOX-H94. |
|
|
Dec 4, 2012 |
1060 |
| Profectus BioSciences' Vesicular Stomatitis Virus-Vectored HIV-1 Vaccine Safe and Immunogenic in Government Sponsored Phase 1 Trial. |
|
|
Dec 4, 2012 |
1174 |
| Aduro Announces Completion of Enrollment in Phase 2 Clinical Trial. |
|
|
Nov 29, 2012 |
399 |
| BioTime CEO Dr. Michael West to Present at World Stem Cell Summit 2012. |
|
|
Nov 29, 2012 |
824 |
| ACT Announces Completion of Higher-Dosage Cohort in Both U.S. Clinical Trials. |
|
|
Nov 28, 2012 |
1080 |
| Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure. |
|
|
Nov 22, 2012 |
1027 |
| Cardio3 BioSciences Receives Authorization to Begin World's First Phase III Clinical Trial in Regenerative Medicine for Heart Failure. |
|
|
Nov 22, 2012 |
1032 |
| Diffusion Pharmaceuticals Successfully Completes Phase I Brain Cancer Trial. |
|
|
Nov 19, 2012 |
771 |
| CytoDyn Announces Phase IIB Clinical Trial Agreement with Dr. Jeffrey Jacobson, Drexel University College of Medicine. |
|
|
Nov 16, 2012 |
1275 |
| Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia. |
|
|
Nov 14, 2012 |
1999 |
| AtheroNova Announces Milestone Filing of IND in Russian Federation. |
|
|
Nov 13, 2012 |
940 |
| Generex Provides Update on Company Initiatives Including the AE37 Breast Cancer Vaccine Program. |
|
|
Nov 13, 2012 |
958 |
| Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials. |
|
|
Nov 8, 2012 |
1066 |
| Pharming, Santarus report encouraging Phase III results for Ruconest in angioedema. |
|
|
Nov 7, 2012 |
191 |
| Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax-Direct Trial. |
|
|
Nov 6, 2012 |
1260 |
| Northwest Bio Collaborating With Leading UK Cancer Institutions For DCVax-Direct Trial. |
|
|
Nov 6, 2012 |
1295 |
| Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma. |
|
Financial report |
Nov 2, 2012 |
819 |
| Millennium and Seattle Genetics Initiate Global Phase 3 Clinical Trial of ADCETRIS[R] in Previously Untreated Advanced Hodgkin Lymphoma. |
|
|
Nov 1, 2012 |
1754 |
| ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD. |
|
|
Nov 1, 2012 |
798 |
| Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma. |
|
Financial report |
Nov 1, 2012 |
766 |
| Disagreement with clinical trial methodology insufficient to claim fraud. |
Beck, Julie |
|
Nov 1, 2012 |
1001 |
| Advaxis Updates Phase 2 Cervical Cancer Trial Data. |
|
|
Oct 31, 2012 |
1130 |
| Enlivex Therapeutics Announces Positive Results in Completion of Clinical Trial for the Treatment of Bone Marrow Transplant Recipients. |
|
Clinical report |
Oct 24, 2012 |
1121 |
| SARcode Bioscience Announces Positive Topline Results from Phase 3 Dry Eye Study of Lifitegrast. |
|
|
Oct 23, 2012 |
937 |
| GlycoMimetics Announces Publication in Nature Medicine of Preclinical Data for Its GMI-1070 Drug Candidate. |
|
|
Oct 22, 2012 |
377 |
| Millennium Initiates Global TOURMALINE-AL1 Pivotal Phase 3 Trial of MLN9708 In Patients with Relapsed or Refractory Primary (AL) Amyloidosis. |
|
|
Oct 19, 2012 |
774 |
| Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS[R] as Front-line Therapy for Hodgkin Lymphoma Patients Age 60 and Over. |
|
|
Oct 17, 2012 |
1576 |
| PROLOR Biotech Announces Positive Results From Preclinical Toxicology Study Of Its Reversible-Pegylation Platform Technology. |
|
|
Oct 16, 2012 |
1118 |
| ArQule and Daiichi Sankyo Reach Agreement with FDA on Special Protocol Assessment for Phase 3 Trial of Tivantinib in Hepatocellular Carcinoma. |
|
Clinical report |
Oct 16, 2012 |
1177 |
| Pharmacyclics Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial. |
|
|
Oct 15, 2012 |
1202 |
| ACT Announces Approval to Treat Additional Stargardt's Disease Patients with Higher RPE Dosage in Both U.S. and European Clinical Trials. |
|
|
Oct 9, 2012 |
922 |
| Ingenuity Systems to Partner with Life Technologies to Develop Solutions for Interpreting Clinical Diagnostic Tests. |
|
|
Oct 3, 2012 |
728 |
| XBiotech Receives Fast Track Designation from FDA for Anti-Cachexia Drug Xilonix(TM). |
|
|
Oct 3, 2012 |
744 |
| TaiGen and Medigen of Taiwan to be in cross-strait drug project. |
Wang, Andrew |
Brief article |
Oct 2, 2012 |
204 |
| Preliminary Phase 1 Data for Cabozantinib in Japanese Patients Presented at ESMO 2012. |
|
|
Sep 30, 2012 |
1096 |
| NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer[R]. |
|
|
Sep 26, 2012 |
1200 |
| Seattle Genetics and Millennium Complete Enrollment in Phase III AETHERA Trial of ADCETRIS[R] for Post-Transplant Patients with Hodgkin Lymphoma. |
|
|
Sep 25, 2012 |
1725 |
| RXi Pharmaceuticals Announces Completion of Dosing in Phase 1 Trial for RXI-109 Program. |
|
|
Sep 24, 2012 |
1248 |
| Maxwell Biotech Venture Fund Invests in POC Clinical Program of a New Anti-Tumor Drug Candidate MBC-11 Targeting Metastatic Bone Disease. |
|
Company overview |
Sep 24, 2012 |
1132 |
| YM BioSciences Reports Fiscal 2012 Operational and Financial Results. |
|
Financial report |
Sep 21, 2012 |
17708 |
| Research and Markets: Exelixis Inc. - Company Analysis: Assess the Potential of Cabozantinib Based on Market Size, Phase III Results, and Future Indications. |
|
|
Sep 21, 2012 |
345 |
| Proteonomix Announces Agreement with the University of Medicine and Dentistry of New Jersey (UMDNJ) to Conduct a Phase 1 Trial with UMK-121 in End-Stage Liver Disease. |
|
|
Sep 14, 2012 |
764 |
| China : MEDIMMUNE forms JV with WUXI APPTEC to develop new biologic. |
|
|
Sep 13, 2012 |
157 |
| China : CHINA DEAL is signed by MedImmune. |
|
|
Sep 13, 2012 |
338 |
| China,United States : Medimmune And Wuxi Apptec Announce Joint Venture To Develop Novel Biologic For Chinese Market. |
|
Company overview |
Sep 10, 2012 |
424 |
| MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market. |
|
|
Sep 10, 2012 |
1509 |
| MedImmune and WuXi AppTec Announce Joint Venture to Develop Novel Biologic for Chinese Market. |
|
|
Sep 10, 2012 |
1594 |
| ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson's Disease Psychosis. |
|
Clinical report |
Sep 5, 2012 |
901 |
| Alnylam Presents Complete Results from Phase IIb Trial with ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. |
|
|
Sep 4, 2012 |
2166 |
| ImmunoGen, Inc. Announces Trastuzumab Emtansine (T-DM1) Significantly Improved Survival in the EMILIA Phase III Trial. |
|
Clinical report |
Aug 27, 2012 |
840 |
| Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma. |
|
|
Aug 24, 2012 |
851 |
| Kineta Announces Regulatory Clearance to Initiate a Phase 1 Clinical Trial for ShK-186. |
|
|
Aug 21, 2012 |
551 |
| PhaseBio Pharmaceuticals Initiates a Multicenter, Randomized Placebo and Active Comparator Controlled Phase 2b Trial to Evaluate use of Glymera for the Treatment of Uncontrolled Type 2 Diabetes. |
|
Clinical report |
Aug 21, 2012 |
456 |
| ACT Announces Scotland's NHS Lothian as Additional Site for EU Clinical Trial Using hESC-Derived RPE Cells for Macular Degeneration. |
|
|
Aug 20, 2012 |
843 |
| Morphotek, Inc. Opens 60,000-square-foot Manufacturing Plant. |
|
|
Aug 14, 2012 |
650 |
| United States : INVISTA and LanzaTech Sign Joint Development Agreement for Bio-Based Butadiene. |
|
|
Aug 14, 2012 |
391 |
| INVISTA and LanzaTech Sign Joint Development Agreement for Bio-Based Butadiene. |
|
|
Aug 13, 2012 |
750 |
| Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis. |
|
|
Aug 8, 2012 |
1446 |
| Diffusion Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Brain Cancer Trial of TSC. |
|
|
Aug 1, 2012 |
494 |
| Lixte Biotechnology Holdings Announces Increased Funding And FDA Allowance To Conduct A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100. |
|
|
Jul 31, 2012 |
668 |
| ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration. |
|
|
Jul 30, 2012 |
891 |
| Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting. |
|
|
Jul 30, 2012 |
1106 |
| Maxwell Biotech Venture Fund's Portfolio Company, Infectex, Receives Russian Regulator's Approval to Conduct Pivotal Clinical Trial for Sequella's Antibiotic, SQ109, for Tuberculosis. |
|
|
Jul 26, 2012 |
976 |
| Exelixis Announces Initiation of Cabozantinib Investigator-Sponsored Trials in Non-Small Cell Lung Cancer and Multiple Myeloma. |
|
|
Jul 26, 2012 |
1187 |
| Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias. |
|
|
Jul 25, 2012 |
814 |
| IntelliCell BioSciences, Inc. New Lab at 460 Park Avenue, New York, NY is cGTP Compliant. |
|
|
Jul 24, 2012 |
1037 |
| ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target. |
|
|
Jul 11, 2012 |
838 |
| NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer[R] NOX-A12 for Treatment of Chronic Lymphocytic Leukemia. |
|
|
Jul 11, 2012 |
1109 |
| FYI From Human Genome Sciences: GlaxoSmithKline Announces Positive Data from Harmony 8 Phase 3 Trial and Completion of Clinical Registration Package for Albiglutide in Type 2 Diabetes. |
|
|
Jul 11, 2012 |
679 |
| ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD. |
|
|
Jul 9, 2012 |
916 |
| Diamyd Medical Reports Results from Phase II Study in Cancer Pain. |
|
Clinical report |
Jul 3, 2012 |
1214 |
| Clinical trials show promise in breast cancer treatment. |
|
Brief article |
Jul 1, 2012 |
239 |
| 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin. |
|
|
Jun 28, 2012 |
538 |
| ProtAffin AG starts Phase 1 study for lead product PA401 in inflammatory lung disease. |
|
|
Jun 27, 2012 |
810 |
| Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status. |
|
|
Jun 25, 2012 |
1014 |
| Seattle Genetics Highlights Updated Survival Data from ADCETRIS[R] Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma. |
|
|
Jun 14, 2012 |
1841 |
| VaxInnate Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu. |
|
|
Jun 12, 2012 |
730 |
| Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma Presented at ASCO. |
|
|
Jun 11, 2012 |
1825 |
| Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial. |
|
|
Jun 11, 2012 |
747 |
| FYI from Human Genome Sciences: GlaxoSmithKline Announces New Data from Phase 3 Studies of Once-Weekly Albiglutide in Type 2 Diabetes. |
|
|
Jun 9, 2012 |
702 |
| Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine. |
|
|
Jun 7, 2012 |
1013 |
| Alnylam Completes Enrollment in Phase I Clinical Trial and Initiates Phase II Clinical Trial of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR). |
|
|
Jun 7, 2012 |
1720 |
| Alnylam Presents Data from its Phase I Extension Study with ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting. |
|
|
Jun 4, 2012 |
2042 |
| Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer. |
|
|
Jun 4, 2012 |
1178 |
| Cabozantinib Meets Primary Endpoint of Progression Free Survival in Phase 3 Pivotal Trial in Medullary Thyroid Cancer. |
|
|
Jun 4, 2012 |
2176 |
| Clinical drug trials challenging, rewarding. |
|
|
Jun 3, 2012 |
687 |
| Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO. |
|
|
Jun 3, 2012 |
1305 |
| ImmunoGen, Inc. Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial. |
|
|
Jun 3, 2012 |
942 |
| Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to Be Presented at ASCO. |
|
|
Jun 2, 2012 |
1744 |
| Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to be Presented at ASCO. |
|
|
Jun 2, 2012 |
1748 |
| Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting. |
|
|
Jun 2, 2012 |
879 |
| Genzyme Reports Positive Top-Line Results of TOWER, a Pivotal Phase III Trial for AUBAGIOTM* (teriflunomide) in Relapsing Multiple Sclerosis. |
|
|
Jun 1, 2012 |
1416 |
| Advaxis Completes Enrollment in Phase 2 Cervical Cancer Study. |
|
Report |
May 29, 2012 |
791 |
| Diamyd Medical's Phase II study in cancer pain fully recruited. |
|
|
May 22, 2012 |
1039 |
| VBL Therapeutics Presents Positive Preclinical Data for VB-201 in Inflammatory Bowel Disease at Digestive Disease Week (DDW) 2012. |
|
|
May 21, 2012 |
760 |
| Active Biotech and Ipsen to Present Tasquinimod Phase II Overall Survival Data at the 2012 ASCO Annual Meeting. |
|
Conference news |
May 18, 2012 |
1344 |
| Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress. |
|
|
May 18, 2012 |
697 |
| Arqule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-small Cell Lung Cancer. |
|
|
May 18, 2012 |
1431 |
| ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase 3 Clinical Trial of Tivantinib in Non-Small Cell Lung Cancer. |
|
|
May 18, 2012 |
1338 |
| Positive Phase 2 Clinical Data With Tivantinib in Hepatocellular Carcinoma to be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology. |
|
|
May 17, 2012 |
1505 |
| Positive Phase 2 Clinical Data with Tivantinib in Hepatocellular Carcinoma to Be Highlighted in Oral Presentation at 2012 Annual Meeting of American Society of Clinical Oncology. |
|
Clinical report |
May 17, 2012 |
1492 |
| Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers. |
|
|
May 15, 2012 |
1244 |
| Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR). |
|
|
May 10, 2012 |
2387 |
| Seattle Genetics Announces Data from Investigator Trial of ADCETRIS[TM] in Relapsed Cutaneous T-Cell Lymphoma. |
|
|
May 10, 2012 |
1784 |
| Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases% Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation. |
|
|
May 10, 2012 |
3198 |
| Advaxis Announces Cancer Research UK Initiates Phase 1/2 Clinical Trial of ADXS-HPV for the Treatment of Head and Neck Cancer. |
|
|
May 8, 2012 |
998 |
| Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS[TM] in Patients with CD30-Expressing Relapsed Cutaneous T-cell Lymphoma. |
|
|
May 7, 2012 |
1836 |
| Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating that Pentraxin-2 Suppressed Fibrosis, Neovascularization, and Vascular Leakage. |
|
|
May 7, 2012 |
781 |
| ACT Announces Massachusetts Eye and Ear as Additional Site for Clinical Trial for Dry Age-Related Macular Degeneration Using Human Embryonic Stem Cell-Derived RPE Cells. |
|
|
May 2, 2012 |
1006 |
| Solazyme and Dow Enter into Contingent Global Commercial Offtake Agreement and Concurrently Sign Phase 2 Joint Development Agreement to Accelerate Commercialization of Bio-based Dielectric Insulating Fluids. |
|
|
May 2, 2012 |
1360 |
| Institute in Philadelphia to participate in a clinical trial. |
|
Brief article |
May 1, 2012 |
190 |
| Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease. |
|
Financial report |
May 1, 2012 |
692 |
| ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Increase RPE Dosage for Stargardt's Disease Patients in U.S. Trial. |
|
|
Apr 24, 2012 |
1072 |
| Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif[R] in Phase III Trial. |
|
|
Apr 24, 2012 |
2977 |
| ACT Announces Third Dry AMD Patient Treated in Clinical Trial. |
|
|
Apr 20, 2012 |
1127 |
| Opexa to Hold Preliminary Investigator's Meeting for MS Trial at American Academy of Neurology Annual Meeting. |
|
|
Apr 19, 2012 |
1123 |
| Viral Genetics April 2012 Shareholder Update Alerts Investors to Product Pipeline Expansion and Developments at Algal BioFuels Subsidiary. |
|
|
Apr 18, 2012 |
587 |
| ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound. |
|
|
Apr 17, 2012 |
802 |
| ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells. |
|
|
Apr 16, 2012 |
689 |
| BioTime CEO Michael D. West to Present at the 8th GTC Stem Cell Summit 2012. |
|
|
Apr 16, 2012 |
855 |
| Spectrum Pharmaceuticals Announces Results of Apaziquone Phase 3 Clinical Trials. |
|
Financial report |
Apr 5, 2012 |
781 |
| ACT Announces Approval of Bascom Palmer Eye Institute as Additional Site for Stem Cell Clinical Trial for dry Age-Related Macular Degeneration. |
|
|
Apr 4, 2012 |
1017 |
| FYI from Human Genome Sciences: GlaxoSmithKline Announces Further Data from Phase 3 Trials of Albiglutide. |
|
|
Apr 3, 2012 |
629 |
| Oncolytics Biotech[R] Inc. Completes Enrollment in First Stage of Phase III Study in Head and Neck Cancers. |
|
Report |
Apr 2, 2012 |
769 |
| ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial. |
|
|
Mar 30, 2012 |
864 |
| Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD). |
|
|
Mar 22, 2012 |
759 |
| Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug. |
|
|
Mar 20, 2012 |
871 |
| Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug. |
|
|
Mar 20, 2012 |
867 |
| Alnylam Initiates Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR). |
|
|
Mar 19, 2012 |
2041 |
| Promedior Receives U.S. Orphan Drug Designation for PRM-151 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). |
|
|
Mar 7, 2012 |
886 |
| Millennium Initiates Pivotal Phase 3 Trial of MLN8237 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma. |
|
|
Mar 6, 2012 |
551 |
| KYTHERA Biopharmaceuticals Announces Initiation of Pivotal U.S. Phase III Clinical Trials to Evaluate ATX-101 for Reduction of Submental Fat. |
|
|
Mar 5, 2012 |
1166 |
| Vitiva and naturamed team up. |
|
Brief article |
Mar 1, 2012 |
224 |
| Oncolytics Biotech[R] Inc. Enters into Sponsorship Agreement with NCIC CTG for Randomized Phase II Study in Prostate Cancer. |
|
Clinical report |
Feb 21, 2012 |
683 |
| Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for Stargardt's Disease. |
|
|
Feb 15, 2012 |
1122 |
| ACT Announces Third Patient with Stargardt's Disease Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells. |
|
|
Feb 13, 2012 |
925 |
| Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration. |
|
|
Jan 17, 2012 |
1328 |
| Three Adimab Antibodies Enter Human Clinical Trials. |
|
|
Jan 11, 2012 |
384 |
| Cubist Pharmaceuticals and Hydra Biosciences Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain. |
|
|
Jan 10, 2012 |
1002 |
| Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials. |
|
Clinical report |
Jan 9, 2012 |
2073 |
| Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin for the Treatment of Transthyretin-Mediated Amyloidosis. |
|
|
Jan 6, 2012 |
2069 |
| Acasti Pharma Initiates 2nd Phase 2 Clinial Study. |
|
|
Dec 31, 2011 |
642 |
| ISRAEL : Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology. |
|
|
Dec 21, 2011 |
370 |
| Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis. |
|
|
Dec 20, 2011 |
1434 |
| Compugen to Broaden and Accelerate Monoclonal Antibody Program for Oncology and Immunology. |
|
|
Dec 20, 2011 |
2045 |
| Bio-Path Holdings' Initial Phase I Data in Leukemia Clinical Trial Demonstrates That Its Neutral Lipid Delivery Technology Antisense Drug BP-100-1.01 (Liposomal Grb-2) is Well Tolerated with Activity Seen at Low Starting Dose. |
|
|
Dec 13, 2011 |
1107 |
| Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS[TM] (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual Meeting. |
|
|
Dec 13, 2011 |
2220 |
| Pharmacyclics Forms Pact to Develop and Commercialize PCI-32765 for Hematologic Cancers with Janssen Biotech, Inc. |
|
|
Dec 8, 2011 |
1084 |
| Alnylam Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. |
|
Clinical report |
Nov 29, 2011 |
1526 |
| Exelixis Announces Initiation of Phase 2 Investigator-Sponsored Trial of Cabozantinib in Women with Hormone Receptor-Positive Metastatic Breast Cancer and Bone Metastases. |
|
|
Nov 21, 2011 |
1722 |
| Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis. |
|
|
Nov 14, 2011 |
2109 |
| Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals. |
|
|
Nov 14, 2011 |
956 |
| Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease. |
|
Clinical report |
Nov 9, 2011 |
1053 |
| Avila Therapeutics Presents Clinical and Preclinical Data on AVL-292 Showing Potential for the Treatment of Autoimmune Disease at the 2011 American College of Rheumatology Annual Scientific Meeting. |
|
|
Nov 8, 2011 |
523 |
| KYTHERA Biopharmaceuticals Presents Long-Term Follow-up Study Results From Phase 2 Trials With ATX-101. |
|
|
Nov 7, 2011 |
1142 |
| ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma. |
|
|
Nov 7, 2011 |
1126 |
| Promedior Presents Preclinical Data at AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect. |
|
|
Nov 7, 2011 |
997 |
| Santaris Pharma A/S Phase 2a Data of Miravirsen Shows Dose-Dependent, Prolonged Viral Reduction of 2-3 Logs HCV RNA After Four-Week Treatment in Hepatitis C Patients. |
|
|
Nov 5, 2011 |
1921 |
| Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis. |
|
|
Nov 2, 2011 |
695 |
| Biotech SIC to kick off operation on Nov. 1. |
Liu, Philip |
Brief article |
Oct 31, 2011 |
244 |
| Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS[TM] in CD30-Positive Non-Lymphoma Malignancies. |
|
|
Oct 25, 2011 |
1220 |
| Exelixis' Cabozantinib Meets Primary Endpoint in Phase 3 Clincial Trial for Medullary Thyroid Cancer. |
|
Clinical report |
Oct 24, 2011 |
1499 |
| Alemtuzumab (Lemtrada[TM]*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study. |
|
|
Oct 22, 2011 |
2221 |
| Oral Therapy Teriflunomide (Aubagio(TM)(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis. |
|
|
Oct 20, 2011 |
1810 |
| BioCancell to Commence Enrollment of Phase IIb Pancreatic Cancer Clinical Trial. |
|
|
Oct 6, 2011 |
518 |
| Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio(TM)(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity. |
|
|
Oct 6, 2011 |
1781 |
| Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio(TM)(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity. |
|
|
Oct 5, 2011 |
1785 |
| Research and Markets: UK and Ireland Biotechnology Sector: Clinical Phase Drug Development Pipeline. |
|
|
Oct 4, 2011 |
701 |
| Initial Data from Bio-Path Holdings' Phase I Clinical Trial Accepted for Presentation at American Society of Hematology Annual Meeting. |
|
|
Oct 4, 2011 |
770 |
| Santaris Pharma A/S to Report New Clinical Data From Miravirsen Phase 2a Study to Treat Hepatitis C in Late-Breaking Oral Presentation at the AASLD 2011 Annual Meeting. |
|
Clinical report |
Oct 3, 2011 |
1354 |
| Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints. |
|
|
Oct 3, 2011 |
1503 |
| Synageva BioPharma Expands International Clinical Trial for Infants with Lysosomal Acid Lipase Deficiency, a Lysosomal Storage Disorder. |
|
|
Sep 28, 2011 |
1139 |
| ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials. |
|
|
Sep 28, 2011 |
1395 |
| Alnylam Initiates Phase I Clinical Study of ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia. |
|
|
Sep 26, 2011 |
2102 |
| Abnova, Clearbridge tie up in cancer-diagnostic device market. |
Liang, Quincy |
Brief article |
Sep 23, 2011 |
232 |
| ACT Receives Approval for First Human Embryonic Stem Cell Trial in Europe. |
|
|
Sep 22, 2011 |
1242 |
| ConjuChem Initiates Phase 2 Study of Diabetes Drug. |
|
|
Sep 14, 2011 |
533 |
| Alnylam Expands "Alnylam 5x15" RNAi Therapeutic Pipeline with ALN-APC, an RNAi Therapeutic Targeting Protein C for the Treatment of Hemophilia. |
|
|
Sep 8, 2011 |
2473 |
| NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease. |
|
|
Sep 6, 2011 |
740 |
| Enlivex completes Trial enrollment for GVHD in transplant. |
|
|
Aug 30, 2011 |
903 |
| Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS[TM] in CD30-Positive Non-Hodgkin Lymphoma. |
|
|
Aug 23, 2011 |
816 |
| First Cohort Successfully Completed in Bio-Path Holdings' Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia. |
|
|
Aug 11, 2011 |
1040 |
| Oncolytics Biotech Clinical Trial Reports Positive Results. |
|
|
Aug 1, 2011 |
429 |
| Alnylam Completes ALN-VSP Phase I Trial in Patients with Liver Cancer. |
|
|
Aug 1, 2011 |
1677 |
| Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment. |
|
|
Aug 1, 2011 |
1871 |
| Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada[TM] (*)) in Multiple Sclerosis. |
|
|
Jul 11, 2011 |
1870 |
| Alnylam Files Clinical Trial Application (CTA) for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia. |
|
|
Jul 11, 2011 |
1815 |
| Almac Expands Global Coverage by Adding Depots for Clinical Trial Supply Distribution to the Asia Pacific Region. |
|
|
Jun 29, 2011 |
518 |
| Sinovac Commences Phase II Clinical Trial for EV71 Vaccine. |
|
|
Jun 28, 2011 |
1207 |
| Diamyd Medical: Diamyd Presents Detailed Results of European Phase III Study. |
|
|
Jun 28, 2011 |
1223 |
| Pharmaceutical Industry Veterans Establish BioEndpoint Consulting to Offer Strategic Insight and Expertise in Commercialization Processes and Drug Development. |
|
|
Jun 27, 2011 |
418 |
| Diamyd Medical: Diamyd Initiates Closure of US Phase III study. |
|
|
Jun 23, 2011 |
1044 |
| MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28. |
|
|
Jun 23, 2011 |
513 |
| Avila Therapeutics Presents Preclinical Data with AVL-292, its Btk Inhibitor, Demonstrating Suppression of Autoimmune Disease Activity. |
|
|
Jun 23, 2011 |
692 |
| Synageva BioPharma Receives FDA Fast Track Designation for SBC-102 for Lysosomal Acid Lipase Deficiency. |
|
|
Jun 23, 2011 |
1329 |
| Clinical Development Plan for Pediatric Use of PROLOR Biotech's Long-Acting Human Growth Hormone has Been Accepted for Review by European Medicines Agency. |
|
|
Jun 20, 2011 |
1122 |
| Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes. |
|
Clinical report |
Jun 14, 2011 |
473 |
| INVO Bioscience Announces Planned Submission To ANVISA For Brazilian Approval Following Completion of Clinical Trial. |
|
|
Jun 14, 2011 |
1215 |
| Third Annual Diversity Summit at the 2011 BIO Convention Convenes to Discuss Disparities in Clinical Trials and Healthcare. |
|
|
Jun 14, 2011 |
777 |
| Interim Data From Phase 2 Trial of AC220 Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations. |
|
|
Jun 13, 2011 |
1358 |
| Interim Data from Phase 2 Trial of AC220 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia with FLT3-ITD Activating Mutations. |
|
|
Jun 13, 2011 |
1344 |
| Millennium and Seattle Genetics Present Clinical Data on ADCETRIS[TM] (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting. |
|
|
Jun 10, 2011 |
1411 |
| Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting. |
|
|
Jun 6, 2011 |
1156 |
| Exelixis' Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer. |
|
|
Jun 6, 2011 |
2855 |
| ImmunoGen, Inc. Announces Positive Clinical Data Presented on IMGN901 in the Treatment of Multiple Myeloma. |
|
|
Jun 5, 2011 |
898 |
| Alnylam Presents Phase I Data for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting. |
|
|
Jun 4, 2011 |
2499 |
| Profectus BioSciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Immunogenicity of a Vesicular Stomatitis Virus-vectored HIV-1 Vaccine. |
|
|
Jun 1, 2011 |
741 |
| The ACTG Immunizes First Subject in Clinical Trial of Profectus BioSciences' Therapeutic HIV DNA Vaccine. |
|
|
May 25, 2011 |
996 |
| Data From a Phase 1 Clinical Trial of Exelixis' Cabozantinib Published in the Journal of Clinical Oncology. |
|
|
May 23, 2011 |
1532 |
| VBL Therapeutics Presents Preclinical Data for VB-111 at the 14th Annual ASGCT Meeting. |
|
|
May 19, 2011 |
706 |
| Cannabis Science Announces Planned Thailand Business Partnership and Clinical Trials for Medical Marijuana. |
|
|
May 18, 2011 |
542 |
| Teva and CureTech Announce Positive Phase II Data from CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma. |
|
|
May 17, 2011 |
1692 |
| TTC's Standard of Care Data Ensures Savings for Most Clinical Trial Procedures, Not Just Oncology. |
|
|
May 12, 2011 |
672 |
| Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol. |
|
|
May 11, 2011 |
1212 |
| Can-Fite Announces a Promising Interim Analysis Data of Its Phase I/II Liver Cancer Study with the CF102 Drug. |
|
|
May 11, 2011 |
466 |
| Diamyd Medical: Diamyd Reports Initial Results from European Phase III Trial in Patients Newly Diagnosed with Type 1 Diabetes. |
|
Clinical report |
May 9, 2011 |
989 |
| Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases. |
|
|
May 4, 2011 |
1005 |
| Santaris Pharma A/S Advances New Cholesterol-Lowering Drug, SPC5001 Inhibiting Exciting New Target PCSK9, Into Phase 1 Clinical Trials for the Treatment of High Cholesterol. |
|
|
May 4, 2011 |
1291 |
| Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002. |
|
|
May 2, 2011 |
575 |
| Cellceutix CEO, Leo Ehrlich, Conducts Interview with "Biotech Stock Trader"; Dr. Paul Ginsberg, (Renowned Patent Attorney) Joins Cellceutix Advisory Board. |
|
|
Apr 18, 2011 |
1002 |
| KBC to review Galapagos rating after discontinued RA clinical trials. |
|
|
Apr 15, 2011 |
139 |
| Galapagos' shares plunge on aborted clinical trial. |
|
|
Apr 15, 2011 |
116 |
| Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease. |
|
|
Apr 14, 2011 |
1714 |
| Liver Cell Infusion Performed for First Time in the United States on Child With Life-Threatening Disorder. |
|
|
Apr 14, 2011 |
1077 |
| VERONA PHARMA PLC - First COPD Trial with RPL554 Begins in Rome. |
|
|
Apr 12, 2011 |
674 |
| Diamyd Medical: Diamyd Results from Phase I Clinical Trial in Cancer Pain Published in Annals of Neurology. |
|
|
Apr 11, 2011 |
773 |
| Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology. |
|
|
Apr 7, 2011 |
1696 |
| Data from Two Mipomersen Phase 3 Trials Presented at ACC. |
|
|
Apr 5, 2011 |
2650 |
| Cardio3 BioSciences Announces Results of the C-Cure(R) Phase II Clinical Trial at the 60th Annual American College of Cardiology Meeting. |
|
|
Apr 5, 2011 |
1416 |
| Alnylam Completes Enrollment in ALN-VSP Phase I Clinical Trial. |
|
|
Mar 31, 2011 |
1383 |
| SINOVAC BIOTECH SUBMITS CLINICAL TRIAL APPLICATION FOR PCV. |
|
|
Mar 29, 2011 |
893 |
| BioInvent International AB: First Patient Dosed in Phase II Clinical Trial for Novel Cardiovascular Drug, BI-204. |
|
Clinical report |
Mar 14, 2011 |
681 |
| Euthymics Bioscience Initiates Triade Trial for Major Depression. |
|
|
Mar 14, 2011 |
920 |
| Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris. |
|
Clinical report |
Mar 10, 2011 |
674 |
| Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group. |
|
|
Mar 10, 2011 |
1026 |
| Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular Edema. |
|
|
Mar 10, 2011 |
2209 |
| Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV). |
|
|
Mar 3, 2011 |
1382 |
| Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy for Front-line Systemic ALCL. |
|
|
Mar 1, 2011 |
1011 |
| Bayhill Therapeutics Announces the Successful Clearance of an IND for BHT-3034 for the Treatment of Myasthenia Gravis. |
|
|
Mar 1, 2011 |
577 |
| Efficacy studies of the future. |
|
|
Mar 1, 2011 |
1414 |
| PolyMedix Successfully Completes Phase 1 Exposure Escalation Safety Study With PMX-30063 Antibiotic. |
|
|
Feb 24, 2011 |
1450 |
| Three-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints. |
|
|
Feb 18, 2011 |
1655 |
| CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis. |
|
|
Feb 17, 2011 |
550 |
| Cabozantinib (XL184) Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Castration-Resistant Prostate Cancer. |
|
|
Feb 17, 2011 |
2414 |
| Diamyd Medical: Last Patient Completes the EU Phase III Study of Diamyd[R] Antigen Based Therapy for Type 1 Diabetes. |
|
Clinical report |
Feb 14, 2011 |
908 |
| Diamyd Medical: Diamyd Phase II Study in Cancer Pain Posted on ClinicalTrials.gov. |
|
Clinical report |
Feb 10, 2011 |
592 |
| PolyMedix Initiates Phase 2 Clinical Trial with Novel Heptagonist, PMX-60056. |
|
|
Feb 9, 2011 |
1136 |
| Human Genome Sciences and GlaxoSmithKline Announce Publication of BLISS-52 Phase 3 Study Results for BENLYSTA[R] in The Lancet. |
|
Clinical report |
Feb 7, 2011 |
763 |
| MACROGENICS BEGINS PHASE I CLINICAL TRIAL OF MGAH22. |
|
|
Feb 1, 2011 |
662 |
| SINOVAC GETS SFDA APPROVAL TO BEGIN EV71 VACCINE TRIALS. |
|
|
Feb 1, 2011 |
724 |
| Maxygen Announces Initiation of Phase I Clinical Trial Under Perseid's Collaboration with Astellas for CTLA4-Ig Program. |
|
|
Jan 31, 2011 |
1079 |
| Verona Pharma Applies for Approval to Test RPL554 in UK Clinical Trials. |
|
|
Jan 31, 2011 |
554 |
| Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial. |
|
|
Jan 28, 2011 |
672 |
| INVO Bioscience Announces Commencement of Clinical Trial in Brazil to Obtain ANVISA Approval. |
|
|
Jan 25, 2011 |
1284 |
| Diamyd Medical: Diamyd Starts Phase II Study in Cancer Pain. |
|
|
Jan 17, 2011 |
758 |
| Independent Data Safety Monitoring Board Gives "Go-Ahead" to Complete Dosing in First Leg of Advaxis' Phase II Cervical Dysplasia Trial. |
|
|
Jan 14, 2011 |
685 |
| EHSI Eyes Opportunity for NASA Bioreactor in OceanBASIS Project. |
|
|
Jan 13, 2011 |
757 |
| Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient into Global Phase 3 Trial for ARQ 197. |
|
Clinical report |
Jan 12, 2011 |
1461 |
| Daiichi Sankyo and ArQule Enroll First Non-Small Cell Lung Cancer Patient Into Global Phase III Trial for ARQ 197. |
|
|
Jan 12, 2011 |
1673 |
| Sangamo BioSciences Announces Completion of Enrollment of Phase 2b Clinical Trial in Diabetic Neuropathy. |
|
|
Jan 10, 2011 |
2017 |
